Aldehyde Dehydrogenase 2 Inhibits Inflammatory Response And Regulates Atherosclerotic Plaque

This study examined how variations in a gene called ALDH2 (aldehyde dehydrogenase 2) affect the development of atherosclerotic plaques - the fatty buildups in arteries that can lead to heart attacks and strokes. Some people have a genetic variation that dramatically reduces their ALDH2 enzyme activity to just 1-6% of normal levels, and previous research had shown these individuals have higher rates of coronary artery disease.

To understand why this happens, researchers conducted experiments using mice engineered to develop atherosclerosis similar to humans. They created three groups: mice with normal ALDH2 levels, mice with artificially increased ALDH2, and mice with reduced ALDH2 activity. The results were striking - mice with reduced ALDH2 developed larger, more dangerous plaques filled with inflammatory cells and unstable materials that make plaques prone to rupturing. In contrast, mice with increased ALDH2 activity had smaller, more stable plaques with less inflammation.

The researchers also studied human blood vessel cells and found that ALDH2 works by controlling inflammatory pathways in the body. When ALDH2 activity is low, inflammatory molecules increase and blood vessel cells become more prone to damage. The enzyme appears to act as a natural anti-inflammatory protector for our cardiovascular system.

This research helps explain why some people may be at higher genetic risk for heart disease and suggests that supporting ALDH2 function could be a therapeutic target. At VALIA Health, this type of genetic insight can inform personalized approaches to cardiovascular risk assessment and potentially guide targeted interventions to reduce inflammation and protect arterial health as part of a comprehensive longevity strategy.